Atossa Therapeutics (ATOS) News Today → Top 5 AI Stocks to Buy for 2024 (From Market Moving Trends) (Ad) Free ATOS Stock Alerts $1.35 -0.19 (-12.34%) (As of 04/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineAtossa Therapeutics (NASDAQ:ATOS) Given Buy Rating at HC Wainwrightamericanbankingnews.com - April 17 at 4:10 AM5 Micro-Cap Healthcare Stocks Insiders Are Buyinginsidermonkey.com - April 16 at 1:24 PMAtossa Therapeutics (NASDAQ:ATOS) Stock Rating Reaffirmed by HC Wainwrightmarketbeat.com - April 16 at 11:29 AMPromising Synergies: Atossa Therapeutics’ Advances in ER+/HER2- Breast Cancer Treatmentmarkets.businessinsider.com - April 15 at 8:37 PMAtossa Therapeutics announces breast cancer trial evaluating lead asset in combination with Eli Lilly drugproactiveinvestors.com - April 15 at 9:22 AMAtossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancerglobenewswire.com - April 15 at 8:30 AMJonathan Finn Buys 25,000 Shares of Atossa Therapeutics, Inc. (NASDAQ:ATOS) Stockinsidertrades.com - April 13 at 6:02 AMAtossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conferenceglobenewswire.com - April 11 at 8:30 AMAtossa Therapeutics Poised for Growth with Promising Breast Cancer Treatmentmarkets.businessinsider.com - April 10 at 10:01 PMAtossa Therapeutics: Strong Buy on Promising EVANGELINE Study Results and Z-endoxifen Efficacy Potentialmarkets.businessinsider.com - April 10 at 12:00 PMAtossa stock climbs 11% on breast cancer drug datamsn.com - April 9 at 3:58 PMAtossa Therapeutics reports positive data from breast cancer treatment trialproactiveinvestors.com - April 9 at 1:02 PMAtossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifenglobenewswire.com - April 9 at 11:59 AMQ1 2024 Earnings Forecast for Atossa Therapeutics, Inc. Issued By HC Wainwright (NASDAQ:ATOS)marketbeat.com - April 4 at 8:48 AMAtossa Therapeutics Inc (ATOS) Year-End Earnings: A Comprehensive Analysisfinance.yahoo.com - April 3 at 7:40 AMAtossa Therapeutics, Inc.: Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Updatefinanznachrichten.de - April 3 at 12:44 AMOptimistic Outlook for Atossa Therapeutics’ Z-endoxifen in Breast Density and Cancer Therapymarkets.businessinsider.com - April 3 at 12:44 AMAtossa Therapeutics (NASDAQ:ATOS) Posts Earnings Resultsmarketbeat.com - April 2 at 8:22 AMPSBJ taking nominations for CFO of the Year through April 5bizjournals.com - April 2 at 4:34 AMATOS Stock Earnings: Atossa Therapeutics Misses EPS for Q4 2023msn.com - April 1 at 11:34 PMAtossa Therapeutics sets sights on breast cancer trial results after strong quarter of clinical milestonesproactiveinvestors.com - April 1 at 4:28 PMAtossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Updateglobenewswire.com - April 1 at 4:00 PMAtossa Therapeutics, Inc. (NASDAQ:ATOS) Sees Large Increase in Short Interestmarketbeat.com - March 31 at 7:32 AMIntroducing the Inno Madness Bracketbizjournals.com - March 28 at 3:36 PMAtossa Therapeutics' breast cancer drug milestone sparks investor enthusiasmproactiveinvestors.com - March 20 at 11:51 AMAtossa Therapeutics back in Nasdaq's good gracesbizjournals.com - March 19 at 8:59 PMAtossa Therapeutics reports successful five-year treatment outcome for breast cancer patient using (Z)-endoxifenproactiveinvestors.com - March 19 at 9:16 AMAtossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for a U.S. Breast Cancer Patientglobenewswire.com - March 19 at 8:30 AMAtossa Therapeutics (ATOS) Set to Announce Earnings on Wednesdaymarketbeat.com - March 19 at 7:25 AMAtossa Therapeutics (NASDAQ:ATOS) Stock Rating Lowered by StockNews.commarketbeat.com - March 18 at 11:17 PMAtossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirementsglobenewswire.com - March 18 at 8:30 AMATOS Apr 2024 4.000 callfinance.yahoo.com - March 16 at 9:59 AMAtossa Therapeutics adds breast cancer expert to boardproactiveinvestors.com - March 12 at 9:53 AMAtossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Directorsglobenewswire.com - March 12 at 8:30 AMATOS Oct 2024 2.000 callfinance.yahoo.com - March 11 at 1:04 PMAtossa Therapeutics to present data from ongoing Phase 2 breast cancer trialproactiveinvestors.com - March 6 at 9:24 AMAtossa Therapeutics, Inc.edition.cnn.com - February 28 at 9:51 PMAtossa Therapeutics Stock (NASDAQ:ATOS), Short Interest Reportbenzinga.com - February 24 at 9:44 AMAtossa Therapeutics, Inc.: Atossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS Studyfinanznachrichten.de - February 22 at 1:10 PMAtossa Therapeutics doses first patient with (Z)-endoxifen in Phase 2 breast cancer trialproactiveinvestors.com - February 22 at 9:56 AMAtossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS Studyglobenewswire.com - February 22 at 8:30 AMAtossa Therapeutics, Inc. (YAG2.SG)au.finance.yahoo.com - February 20 at 3:57 PMATOS Mar 2024 1.000 putfinance.yahoo.com - February 17 at 2:26 AMAtossa Therapeutics, Inc. (NASDAQ:ATOS) to Post FY2023 Earnings of ($0.23) Per Share, HC Wainwright Forecastsmarketbeat.com - February 14 at 7:42 AMAtossa spikes as H.C. Wainwright starts at Buy on lead assetmsn.com - February 12 at 4:52 PMHC Wainwright Initiates Coverage on Atossa Therapeutics (NASDAQ:ATOS)marketbeat.com - February 12 at 8:19 AMAtossa Therapeutics Announces Full Enrollment of (Z)-Endoxifen Arm of I-SPY 2 Clinical Trialfinance.yahoo.com - February 7 at 12:00 PMAtossa Therapeutics (NASDAQ:ATOS) Stock Passes Above 200-Day Moving Average of $0.81marketbeat.com - February 6 at 3:36 AMAtossa Therapeutics progresses Phase II preventative breast cancer therapymsn.com - January 27 at 4:59 AMTraders Purchase Large Volume of Atossa Therapeutics Call Options (NASDAQ:ATOS)marketbeat.com - December 29 at 12:17 PM Get Atossa Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATOS and its competitors with MarketBeat's FREE daily newsletter. Email Address Top 5 AI Stocks to Buy for 2024 (Ad)5 Best AI Stocks to Invest In Investors are getting very rich in AI stocks right now. Wall Street legend is giving away the name and ticker of the little-known AI stock Wall Street is currently buying hand-over-fist. Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In" ATOS Media Mentions By Week ATOS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ATOS News Sentiment▼0.380.39▲Average Medical News Sentiment ATOS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ATOS Articles This Week▼102▲ATOS Articles Average Week Get Atossa Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATOS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: CDT News GALT News NKTR News OVID News HOWL News ME News IMMP News GOSS News RIGL News ACRV News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ATOS) was last updated on 4/18/2024 by MarketBeat.com Staff From Our Partners[Urgent!] Generational Wealth GameplanCrypto 101 MediaHe Is Giving Away BitcoinCrypto Swap ProfitsThe “Perfect Storm” for GoldGold Safe ExchangeBiden out June 13; Kamala won’t replace him?Paradigm PressTop 5 AI Stocks to Buy for 2024Market Moving TrendsTop 5 Tech Stocks to Buy for 2024Daily Market AlertsUrgent alert: open this for a huge profit potentialTimothy SykesYour Money is Not SafeAmerican Alternative Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atossa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.